Dianthus Therapeutics Inc(DNTH) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -4.15 | Insider Own | 16.86% | Shs Outstand | 54.8M | Perf Week | 0.98% |
| Market Cap | 4.45B | Forward P/E | - | EPS next Y | -21.42% | Insider Trans | -3.39% | Shs Float | 46.5M | Perf Month | -9.46% |
| Enterprise Value | 3.56B | PEG | - | EPS next Q | -0.94 | Inst Own | 116.66% | Short Float | 19.32% | Perf Quarter | -23.6% |
| Income | -0.19B | P/S | 2341 | EPS this Y | 9.77% | Inst Trans | -1.4% | Short Ratio | 10.89 | Perf Half Y | -4.96% |
| Sales | 0.00B | P/B | 3.72 | EPS next 5Y | -10.34% | ROA | -24.98% | Short Interest | 8.99M | Perf YTD | 92.96% |
| Book/sh | 21.39 | P/C | 5.02 | EPS past 3/5Y | 49.46% 31.21% | ROE | -26.07% | 52W High | -32.54% ($117.88) | Perf Year | 137.23% |
| Cash/sh | 15.85 | P/FCF | - | Sales past 3/5Y | -31.8% - | ROIC | -16.39% | 52W Low | 146.34% ($32.28) | Perf 3Y | 568.24% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -27.57% | Gross Margin | 80.09% | Volatility(W/M) | 3.77% 4.8% | Perf 5Y | -22.95% |
| Dividend TTM | - | EV/Sales | 1874.94 | Sales Y/Y TTM | -60.77% | Oper. Margin | -11441.39% | ATR (14) | 4.07 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 26.1 | EPS Q/Q | -1.51% | Profit Margin | -10096.95% | RSI (14) | 39.84 | Recom | 1.05 |
| Dividend Gr. 3/5Y | - | Current Ratio | 26.1 | Sales Q/Q | 294.3% | SMA20 | -1.45% ($80.69) | Beta | 1.47 | Target Price | $138.53 |
| Payout | - | Debt/Eq | 0 | Earnings | 2026/8/4 | SMA50 | -15.93% ($94.59) | Rel Volume | 0.91 | Prev Close | $79.33 |
| Employees | 92 | LT Debt/Eq | 0 | EPS/Sales Surpr. | -6.35% 156.06% | SMA200 | -5.83% ($84.44) | Avg Volume(3M) | 0.83M | Price | $79.52 |
| IPO | 2018/6/21 | Option/Short | Yes/Yes | Trades | 8773 | Volume | 748,410 | Change | 0.24% |
This is a clinical-stage biotech company developing therapeutics for autoimmune neuromuscular diseases based on complement inhibition. Its lead candidate is an antibody that selectively blocks the classical complement pathway, and it is being developed for indications such as myasthenia gravis and other autoimmune neuromuscular disorders. The company focuses on creating new drugs designed for convenient self-administered subcutaneous injection.
Over the past 1 year, roughly in the middle
33% below its 1-year high.
Traded about as much as usual. That is 91% of its average volume.
DNTH has a sound balance sheet but weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Growth has stalled
Earnings are expected to grow by +9.8% this year.
Tap to view numbers
Relative to sales, it looks expensive
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $234,100. Peers typically go for $1,648.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -22.9%. The S&P 500 did +70% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 116.7%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
It ranks #56 of 594 in the industry
Based on market cap of $4B.
DNTH#56 Dianthus Therapeutics Inc $4B PER - 
EWTX#57 Edgewise Therapeutics Inc $4B PER - 
LEGN#58 Legend Biotech Corp ADR $4B PER - 
ABCL#59 AbCellera Biologics Inc $4B PER - 
RLAY#60 Relay Therapeutics Inc $4B PER - 
FAQ
What kind of company is DNTH?
DNTH belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of DNTH?
The market cap of DNTH is approximately $4.4B, ranking 1,441 within its sector.
What is the 52-week high and low for DNTH?
DNTH has recorded a 52-week high of $117.88 and a low of $32.28.
